CRP and myeloid sarcoma: A prospective study design would allow for the collection of standardized and comprehensive data, including additional biomarkers like homocysteine and C-reactive protein (CRP), which could provide a more complete picture of systemic inflammation and cardiovascular risk in MS patients.